The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Cell Therapy To Prevent And Treat Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$260,302.00
Summary
In bone marrow transplantation, donor immunity can fight the cancer but can also attack healthy tissues, causing graft-versus-host disease (GVHD). We will use two types of cell therapy to treat GVHD. The first study will use a safety switch called inducible capase 9 (iCasp9) to enable the donor immune cells to be rapidly eliminated if GVHD occurs. The second study will use regulatory T cells to treat patients with chronic GVHD. If successful, these treatment approaches will make transplantation ....In bone marrow transplantation, donor immunity can fight the cancer but can also attack healthy tissues, causing graft-versus-host disease (GVHD). We will use two types of cell therapy to treat GVHD. The first study will use a safety switch called inducible capase 9 (iCasp9) to enable the donor immune cells to be rapidly eliminated if GVHD occurs. The second study will use regulatory T cells to treat patients with chronic GVHD. If successful, these treatment approaches will make transplantation safer.Read moreRead less
Customized IPS Cell Therapy For Recessive Monogenic Retinal Degenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$350,714.00
Summary
The focus of this study is to develop a personalised treatment for certain types of retinal degenerative disease (RDD). Stem cells will be generated from the skin cells obtained from an individual with RDD. Gene therapy will then be applied to correct the underlying disease-causing mutation in the patient cells. The repaired cells will be used to generate retinal cells, which will subsequently be tested in naturally occurring RDD rodent models to determine if they have any beneficial effects.
Identification Of Novel Regulatory Factors In Midbrain Development To Improve Cell Therapies For The Treatment Of Parkinson’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$311,860.00
Summary
Cell transplantation is one of the most promising therapeutic strategies for the treatment of Parkinson’s disease. Cells are transplanted directly into the brain of the patient and can compensate for those lost to the disease. In this project we are identifying new genes that regulate the normal development of the transplanted cells in mice. We hope to use this knowledge to improve the reliability and effectiveness of the approach, bringing the therapy closer to the clinic.
Interactions Between Aberrant Transcriptional Programs And Methylation In Primary Myelodysplasia And Leukaemia.
Funder
National Health and Medical Research Council
Funding Amount
$316,449.00
Summary
Impaired development of blood stem cells leads to haematological disease such as leukaemia. State of the art next-generation sequencing and bioinformatics identified molecular pathways essential for normal blood development and a core set of these genes repressed in leukaemia. Understanding the mechanism by which these genes are re-activated by the non-specific drug azacitidine contributes to the development of new therapeutics with increased efficiency and reduced side effects.
Kinetics, Mechanism And Engraftment Of In Vitro Generated T Cell Precursors As A Strategy To Enhance Thymic Rejuvenation Following Allogeneic Hematopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$403,324.00
Summary
Immune regeneration - following standard cancer therapies such as chemotherapy and radiation-therapy for hematopoietic (blood) stem cell transplant (HSCT) - is one of the most significant unmet clinical challenges today. This research will focus on using “off the shelf” precursor T cells to improve immune reconstitution following HSCT, thereby significantly reducing the incidence of morbidity and mortality following transplantation.
Lymphoid Organ Development: Synthetic Organogenesis Of Artificial Spleen And Characterisation Of Tissue-specific Hematopoiesis
Funder
National Health and Medical Research Council
Funding Amount
$350,232.00
Summary
Spleen is an organ which filters blood circulating around the body and provides immune protection against blood-borne pathogens. Research into spleen development will attempt to synthesise artificial spleen tissue, leading to possible tissue replacement therapies or enhancement of immunity towards infection or cancer. Cellular development in spleen will also be investigated with a view to identifying novel white blood cell subsets that have potential for becoming new targets for immunotherapy.
Investigating The Potential Of Human Stem Cells To Repair The Degenerating Auditory Nerve After Deafness
Funder
National Health and Medical Research Council
Funding Amount
$310,787.00
Summary
One in four Australians is predicted to experience some form of hearing loss by 2050. Hearing loss is irreversible and the chief clinical treatment available for severe to profound hearing loss is a cochlear implant. However, cochlear implant efficacy is limited by the degeneration of the auditory nerve following hearing loss. Using stem cells, this project will develop techniques to restore function to the auditory nerve through replacement of the specialised cells that comprise it.